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1607-551X/Copyright ª 2016, Kaohsiu
CC BY-NC-ND license (http://creativAbstract The aim of this study was to investigate the effect of long-term intake of Tartary
buckwheat tea on the pharmacokinetics (PK) of eplerenone in rats. A validated high-
performance liquid chromatography-mass spectrometry (HPLC-MS) method was established to
determine the eplerenone in plasma, and the portal vein absorption model was applied to
conduct the pharmacokinetic study. Two groups of animalsdbuckwheat tea group and control
groupdwere involved in this study. Plasma samples were obtained at different time points after
administration, and were separated on Shimadzu HPLC-MS 2020 instruments. The method
showed good linearity (rZ 0.9988) over a wide dynamic range (0.20e50 mg/mL). Within- and
between-batch precisions ranged from 2.13% to 7.90%. The extraction recovery rates ranged
from 91.96% to 94.96%. The data showed that in the Tartarian buckwheat group the area under
the curve and maximum concentration of eplerenone were reduced compared with those of the
blank group (p< 0.01), but the time to reach peak concentrations of eplerenone (p< 0.01) was
prolonged. The results suggested that long-term consumption of Tartary buckwheat tea might
induce the activities of the hepatic drug metabolizing enzyme, which can accelerate the meta-
bolism of eplerenone. According to the results, the dosage of eplerenone should be adjusted in
hypertension treatment trials when administeredwith Tartary buckwheat or Tartary buckwheat-
containing dietary supplements to avoid potential drug interactions.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).eclare no conflicts of interest.
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Tartary buckwheat, a driedmature seed of Fagopyrumgenera
in the Polygonaceae family, is mainly produced in south-
western and northern China. It is rich in flavonoids, oleic acid,
vitamins, niacin, and dietary fiber [1,2]. The amount of fla-
vonoids in Tartarybuckwheat is 10e100 times higher than that
of other buckwheat species, in which rutin makes up 70e90%.
Previous studies reported that flavonoids in Tartary buck-
wheat have hypoglycemic, serum lipid-lowering, and anti-
hypertensive effects [3,4]. As a result, Tartary buckwheat tea
has become a popular healthy drink in recent years. It is re-
ported that the main bioactive ingredients of Tartary buck-
wheatdrutin, quercetin, kaempferol, and naringin [5,6], are
inhibitors or activators of CYP3A4, CYP1A1, andCYP1A2 of the
cytochrome P450 (CYP450) system [7e10]. Eplerenone, a
type of a selective aldosterone receptor blocker, is mainly
metabolized by CYP3A4 and has been used for the treatment
of hypertension for a long time [11,12]. In clinics, rutin and
quercetin frequently result in the emergence of drugedrug
interactions by affecting the activities of drug-metabolizing
enzymes [13e15]. If eplerenone is simultaneously coad-
ministered with buckwheat tea to patients, the bioavail-
ability and metabolism of eplerenone can be affected.
The purpose of this study is to investigate whether the
long-term administration of buckwheat tea could affect the
pharmacokinetic (PK) profile of eplerenone in rats. A vali-
dated high-performance liquid chromatography-mass
spectrometry (HPLC-MS) method was established to deter-
mine the eplerenone in plasma, and the portal vein ab-
sorption model was applied to conduct the pharmacokinetic
study. Two groups of animals, the buckwheat tea group and
the control group, were used in the study. The result of this
study was expected to provide an experimental foundation
for the coadministration of eplerenone and buckwheat tea
in the clinical treatment of hypertension.Materials and methods
Chemicals and reagents
Tartarian buckwheat tea was purchased from Zhengzhong
Food Co., Ltd (Xichang, China). Eplerenone, rutin, and
quercetin, were purchased from the National Institutes for
Food and Drug Control (Beijing, China). Astragaloside (IS) was
purchased from Sigma Chemical Co. (St. Louis, MO, USA). b-
Cyclodextrin, sodium phosphate buffer solution, and sodium
chloride were purchased from Beijing Chemical Corporation
(Beijing, China). HPLC-grade acetonitrile andmethanol were
obtained from Fisher Scientific (Iowa, USA). HPLC-grade for-
mic acid was purchased from Kelong Chemical Industry
(Chengdu, China), and ultrapure water was produced using a
Millipore Milli-Q system (Millipore, Billerica, MA, USA). All the
other reagents used were of reagent grade. The chemical
structures of eplerenone and IS are shown in Figure 1.
Animal
Male SpragueeDawley rats of specified pathogen free (SPF)
grade were obtained from the Laboratory Animal Center ofSichuan Health Science Academy (Certificate No. SCXK
2004-6). The rats were housed in an animal room with air
conditioning (22e24C) and free access to food and water.
Treatment of all animals was in accordance with the Na-
tional Institutes of Health Guide to the Care and Use of
Laboratory Animals. The experiments were carried out
under the approval of Experiment Administration Commit-
tee of Sichuan Health Science Academy.
Drug administration
The Tartarian buckwheat water solution for the experiment
was prepared by boiling 17.8 g Tartarian buckwheat with 10
times of water for 5 minutes, followed by another 10-
minute boiling cycle with 5 times of water. The solution was
combined and concentrated to 100 mL. After centrifugation
at 13,500g for 5 minutes, the clear supernatant was filtered
by 0.22-mm (pore size) membrane. The filtrate was
considered Tartarian buckwheat test solution, with a con-
centration of 0.178 g/mL.
We also prepared a lower concentration of Tartarian
buckwheat solution as a substitute for the drinking water of
the animals. Specifically, 5.34 g Tartarian buckwheat was
treated under two boiling cycles (40 times of water for 5
minutes and 45 times of water for 10 minutes). The com-
bined solution was concentrated to 300 mL, with a con-
centration of 0.0178 g/mL.
Eplerenone physic liquor was prepared by dissolving 1 g
of eplerenone in 100 mL of a mixed solution that consisted
of 15% b-cyclodextrin, 0.07 mol/L sodium phosphate buffer
solution (pH 7.4), and 0.5% sodium chloride.
Animal experiment and drug administration
After 1 week of acclimatization, 20 male SpragueeDawley
rats (200e220 g) were randomly divided into the blank
group and the Tartarian buckwheat group (10 rats in each
group). Rats in the Tartarian buckwheat group were
administered with Tartarian buckwheat water solution
[1.78 g/kg, intragastric gavage (i.g.)] twice a day for 29
days. During these days, the lower concentration buck-
wheat solution substituted for the animals’ drinking
water. Rats were fasted for 12 hours prior to the exper-
iment with drinking water supply as usual. Rats in the two
groups were orally administered with eplerenone solution
(100 mg/kg). The blood samples (0.2 mL) were obtained
15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4
hours, 6 hours, 8 hours, and 10 hours after the adminis-
tration. The blood samples were preserved in a 37C
water bath for 20 minutes and then centrifuged at
3500 rpm for 10 minutes. The upper phase was trans-
ferred and preserved in a refrigerator (at 80C) for
future analysis.
Sample preparation
Rat plasma sample (20 mL) was transferred into 4-mL tubes
prior to adding 20 mL IS. The mixture was vortexed for 10
seconds, and acetonitrile (2 mL) was then added to form an
emulsion. The emulsion was vortexed for 3 minutes fol-
lowed by centrifugation at 4000 rpm for 8 minutes. The
Eplerenone Astragaloside
Figure 1. Chemical structures of eplerenone and astragaloside.
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centrifuged at 13,400 rpm for 3 minutes. The upper phase
was transferred into an injection vial for HPLC-electrospray
ionization (ESI)-MS analysis.
Quantitative analysis of Tartarian buckwheat water
solution
Quantitative analysis was carried out on a 1260 Agilent
HPLC system. Chromatography separation was performed
on an Agilent Zorbax SB-C18 guard column
(12.5 mm 4.6 mm inner diameter (i.d.), 5 mm). The multi
wavelength detector (MWD) was operated at 375 nm, and
the column temperature was set at 30oC. Then, 20 mL
Tartarian buckwheat water solution was eluted at a flow
rate of 0.8 mL/min, using a mobile phase of 0.2% (v/v)
phosphoric acid in water and acetonitrile. The proportion
of acetonitrile in the mobile phase was optimized as fol-
lows: 0e8 minutes, 28%; 8e18 minutes, 50%; 18e30 mi-
nutes, 100%; 30e35 minutes, 100%; 35e38 minutes, 28%.
Quantitative and qualitative analysis of plasma
samples
Chromatography separation was performed on an Agilent
Poroshell 120 EC-C18 column (2.7 mm, 4.6 100 mm) using
a Shimadzu HPLC-MS 2020 system (Shimadzu MS Technolo-
gies, Japan), which was equipped with a binary solvent
delivery system, an online vacuum degasser, an autosam-
pler, an ultraviolet detector, a column oven, and labsolu-
tion 5.5 chromatographic work station. The column was
maintained at 30oC and eluted at a flow rate of 1.0 mL/min,
using a mobile phase consisting of 10 mmol/L ammonium
acetate in water and acetonitrile. The proportion of
acetonitrile in the mobile phase was 70%.
Mass spectrometry was carried out on a Shimadzu 2020
mass spectrometer with an ESI interface operating in pos-
itive ion mode.Stock solutions, calibration standard, and quality
control samples
Stock solutions of rutin and quercetin were prepared at
350 mg/mL in methanol. A stock solution of eplerenone was
prepared at 500 mg/mL in methanol. The IS solution was
prepared at 53.10 mg/mL in methanol. Calibration curves
were prepared by spiking 20 mL of an appropriate working
solution into 1.5-mL tubes, evaporating to dryness under a
nitrogen stream, and spiking with 100 mL of blank rat
plasma. The effective concentrations were 0.20, 0.50, 2, 5,
10, 20, and 500 mg/mL of eplerenone. Quality control (QC)
samples were prepared in pool as a single batch for each
concentration at concentrations of 0.20, 10, and 50 mg/L
for eplerenone, and then divided into aliquots and stored in
the freezer at 20C. The IS working solution of 5.31 mg/mL
was diluted from stock solution as needed. The rat plasma
sample (calibration standards and QCs) were treated
following the sample processing procedure.
Data analysis
Kinetica 5.0.11 software (Thermo Electron Corporation,
USA) was used to fit the model. Maple15 software (Maple
Corporation, Japan) was used to perform statistical anal-
ysis. One-way analysis of variance was carried out to
compare data interclass. The least significant difference
(LSD) test was appropriate to equal variance and Tamhane’s
T2 test was appropriate to heterogeneity of variance. A p
value < 0.05 was considered significant.Results
Method validation
The method for determination of eplerenone in rat plasma
by HPLC-MS was validated to meet the guidelines of the
180 L. Zou et al.International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for
Human Use and acceptance criteria as the guidance from
the Food and Drug Administration.
Specificity
IS was chosen as the internal standard for eplerenone
quantitation because of the similar chromatographic
behavior with eplerenone. The typical HPLC chromatograms
of blank plasma spiked with eplerenone/IS, and a sample
obtained from an experimental rat at 1.5 hours after an oral
administration of eplerenone solution (100 mg/kg) are
shown in Figure 2. Under the assay conditions, eplerenone
and IS were completely separated, and no endogenous
substances interfered with eplerenone and IS in the plasma
samples prepared from six different rats (Figure 2).
Calibration curves and limit of detection
The standard curve, established by plotting peak area ra-
tios (y) of eplerenone to IS against analyte concentrations
(x), exhibited good linearity over the concentration range
of 0.20e50 mg/mL. The regression equation for eplerenone
was yZ 1.5006x  0.0850. The lower limit of quantitation
(LLOQ) for eplerenone was defined as 0.10 mg/mL based on
Signal/Noise (S/N)Z 10, and the limit of detection was
estimated as 0.02 mg/mL based on S/NZ 3. According to
our previous analysis, 0.20 mg/mL eplerenone is suitable for
the pharmacokinetic study and was selected as the lowest
concentration on the calibration curves.
Precision and accuracy
The intraday and interday precision and accuracy for
eplerenone were evaluated by assaying three QC levels
(0.20, 10, and 50 mg/mL) on 6 consecutive days, and five
samples were prepared for every level. The results are
presented in Table 1. For each QC level of eplerenone, the
intraday precision was lower than 7.51%, and the accuracy
was between 95.16% and 101.67%; the interday precision
was lower than 7.90%, and the accuracy was between
96.67% and 97.83%. These data suggested that the method
was accurate and precise for the analysis of eplerenone in
rat plasma samples.
Recovery
The extraction recovery of eplerenone was determined at
three QC levels. Recovery was calculated by comparing the
analyte/IS peak area ratios of each analyte in plasma sam-
ples to those in the matrices by spiking the extracted
analyte-free plasma samples prior to chromatography. Re-
covery was calculated using the following formula: recovery
(%)Z concentration found/concentration spiked 100%.
The recovery rates of eplerenone were 94.96 6.65%,
91.96 1.96%, and 93.29 4.21% (nZ 3) at concentrations
of 0.20, 10, and 50 mg/mL, respectively (Table 2).Stability
Stability was evaluated at three QC levels. The stability of
standard solutions was tested at room temperature for 2
hours and upon refrigeration (4C) for 30 days. The stability
of analytes was examined by keeping eplerenone QC sam-
ples in the autosampler tray for 24 hours and in a freezer at
20C for 30 days; the freezeethaw stability was obtained
over three freezeethaw cycles, by thawing at room tem-
perature for 2e3 hours and then refreezing at 20C for
12e24 hours. For each concentration and each storage
condition, six replicates were analyzed in one analytical
batch. The concentration of analytes after each storage
period was related to the initial concentration, which was
determined when the samples were originally prepared and
processed. Results are shown in Table 3. The results of the
stability tests indicated that the standard solutions are
stable at room temperature for 2 hours (relative standard
deviation (RSD)< 7.98%) and upon refrigeration (4C) for 30
days (RSD< 7.90%). The analytes were stable in plasma
samples for 24 hours (RSD< 7.18%) and in a freezer at
20C for 30 days (RSD< 6.04%). The freezeethaw stability
was obtained over three freezeethaw cycles (RSD< 5.78%).Quantitative analysis of Tartarian buckwheat water
solution
Quantitative analyses of rutin, isoquercitrin, quercetin, and
kaempferol were carried out. The typical chromatograms of
the Tartarian buckwheat water solution are shown in
Figure 3. The content of rutin, isoquercitrin, quercetin, and
kaempferol was determined to be 9.05, 0.25, 0.71, and
0.04 mg/g, respectively.Pharmacokinetic and PK parameters analysis
The method was applied to the quantification of epler-
enone in rat plasma samples after i.g. administration. The
mean concentrationetime curves of eplerenone after the
administration of 100 mg/kg (i.g.) to the control and
buckwheat tea groups are shown in Figure 4; the main
pharmacokinetic parameters were calculated and are
shown in Table 4.
One-way analysis of variance was carried out for statis-
tical analysis to compare the data of the two groups. Ac-
cording to the data shown in Table 4, the maximal
concentration of eplerenone (Cmax) was observed at
33.36 3.35 mg/mL in the buckwheat tea group and
43.62 3.24 mg/mL in the control group. The time to reach
peak concentrations of eplerenone (Tmax) was observed at
1.00 0.00 hours in the buckwheat tea group and
0.50 0.00 hour in the control group. The area under the
curve of eplerenone (AUClast) was 50.31 4.28 mg h/mL in
the buckwheat tea group and 58.79 8.03 mg h/mL in the
control group. The mean retention time for eplerenone was
2.01 0.07 hours in the buckwheat tea group and
2.17 0.13 hours in the control group.
Figure 2. Typical HPLC-MS chromatograms. (A) Blank SpragueeDawley rat plasma spiked with astragaloside (IS); (B) blank
SpragueeDawley rat plasma spiked with eplerenone; (C) blank SpragueeDawley rat plasma spiked with eplerenone and IS; and (D)
SpragueeDawley rat plasma obtained from an experiment rat at 1.50 hours after an oral administration of eplerenone solution
(100 mg/kg). Peak 1Z IS; Peak 2Z eplerenone. HPLC-MSZ high-performance liquid chromatography-mass spectrometry.
Coadministration of eplerenone and buckwheat tea 181
Table 1 Accuracy and precision for the determination of eplerenone in plasma samples (nZ 6).
Concentration (mg/mL) Intraday Interday
Mean  SD (mg/mL) Precision (%) Accuracy (%) Mean  SD (mg/mL) Precision (%) Accuracy (%)
0.20 0.20  0.02 7.51 101.67 0.19  0.02 7.90 96.67
10.00 9.87  0.21 2.13 98.70 9.77  0.45 4.65 97.72
50.00 47.58  1.74 3.67 95.16 48.91  2.21 4.52 97.83
SDZ standard deviation.
Table 2 Recovery of eplerenone in plasma samples
(nZ 3).
Concentration (mg/mL) Recovery
Mean  SD (%) RSD (%)
0.20 94.96  6.65 6.99
10.00 91.96  1.96 2.13
50.00 93.29  4.21 4.51
RSD Z relative standard deviation; SDZ standard deviation.
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Studies have demonstrated that eplerenone was well
absorbed and rapidly metabolized after oral administration
[16]. In our work, the value of Tmax was consistent with that
found in some previous studies, but the Cmax of eplerenone
was much higher. It is most likely that eplerenone was
dissolved in the sulfobutyl-b-cyclodextrin solution, which
can be a good package for the drug molecule, forming a
noncovalent complexes and enhancing the stability and
water solubility of eplerenone.
CYP450 is considered to be the most important drug-
metabolizing enzyme system in the body. Various studies
have demonstrated that quercetin is an inhibitor of CYP3A4
and that it inhibits CYP3A4 enzyme activity in aTable 3 Stability of eplerenone (nZ 6).
Storage conditions Conc. added (mg/mL)
Standard solution

























Conc.Z concentration; QCZ quality control; RSD Z; RTZ room temconcentration-dependent manner [8,14]. However, some
studies suggest that different components of flavonoids
may exert different effects on the hepatic microsomal
monooxygenase system according to the route and the
duration of administration [17]. An earlier study showed
that there was no significant difference in Phase I or Phase
II enzyme activities when quercetin was given for 14 days at
a concentration of 1%. In contrast, the liver weight, protein
content of microsomal and cytoplasmic, and activity of
cytochrome P450 were substantially increased when 0.25%
flavone was given [18].
It has been known that 6b-hydroxy eplerenone and 21-
hydroxy eplerenone are the major metabolites in vitro in
both humans and dogs, and that the metabolism of epler-
enone was primarily mediated by CYP3A4 in humans and
CYP3A12 in dogs [11]. However, 6b-OH eplerenone was the
major metabolite in rats, and eplerenone metabolism to
6b-OH eplerenone (EP) was mediated primarily by CYP3A
[12]. The results from our study clearly demonstrated that
long-term coadministration of Tartary buckwheat tea can
significantly reduce the Cmax and AUC, extend the Tmax, and
accelerate the elimination of eplerenone. The reduced
bioavailability of eplerenone as a result of its coadminis-
tration with Tartary buckwheat suggested that Tartary
buckwheat may promote the first-pass metabolism of
eplerenone. It is predicted that long-term consumption of
Tartary buckwheat tea might induce the activities of the
hepatic drug-metabolizing enzyme.Conc. found (mg/mL) Accuracy (%) RSD (%)
0.20  0.01 98.33 5.87
9.70  0.53 97.03 5.49
47.91  3.82 95.83 7.98
0.19  0.02 96.67 7.90
10.05  0.48 100.50 4.78
47.58  3.25 95.16 6.83
0.19  0.01 93.83 3.26
9.88  0.71 98.83 7.18
48.91  2.07 97.82 4.22
0.19  0.01 93.67 3.56
10.18  0.61 101.83 6.04
50.24  2.72 100.49 5.41
0.19  0.01 93.50 3.86
10.22  0.59 102.17 5.78
48.58  1.74 97.16 3.59
perature.
Figure 3. Typical chromatograms. (A) Reference solution; and (B) Tartarian buckwheat water solution. Peak 1Z rutin; Peak
2Z isoquercitrin; Peak 3Z quercetin; Peak 4Z kaempferol.
Figure 4. Mean concentrationetime profiles of eplerenone in rat plasma (nZ 10) obtained in control group and Buckwheat tea
group.
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Table 4 Pharmacokinetic parameters of eplerenone in
rats (nZ 10).
Parameters Control group Buckwheat tea group
Cmax (mg/mL) 43.62  3.24 33.36  3.35**
Tmax (h) 0.65  0.24 1.00  0.00**
AUClast (mg h/mL) 58.79  8.03 50.31  4.28*
AUCextra (mg h/mL) 0.92  0.15 0.59  0.11**
AUCtot (mg h/mL) 59.71  8.12 50.89  4.38*
%AUCextra (%) 1.55  0.20 1.15  0.16**
T1/2 (h) 1.47  0.16 1.25  0.03*
MRT (h) 2.17  0.13 2.01  0.07*
Buckwheat tea group apply t test to control group.
*p< 0.05, **p< 0.01.
AUCZ area under the curve; CmaxZmaximum concentration;
MRTZmean retention time; TmaxZ time to reach peak con-
centrations of eplerenone; T1/2 Z half-life period.
184 L. Zou et al.The results of the current study strongly indicate that
the dosage of eplerenone should be adjusted in hyperten-
sion treatment trials when administered with Tartary
buckwheat or Tartary buckwheat-containing dietary sup-
plements to avoid potential drug interactions.
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